Intranasal administration of nanostructured lipid carriers containing CNS acting drug: Pharmacodynamic studies and estimation in blood and brain

Journal of Psychiatric Research

Volumn 46, Issue 9, 2012, Pages 1133-1138

  Alam, M Intakhab ^a   Baboota, Sanjula ^a   Ahuja, Alka ^a   Ali, Mushir ^a   Ali, Javed ^a   Sahni, Jasjeet K ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Climbing; DLX NLC; FST; Immobility; LAT; Pharmacodynamic studies

Indexed keywords

DRUG CARRIER; DULOXETINE; NANOSTRUCTURED LIPID CARRIER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; FORCED SWIMMING TEST; LOCOMOTION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 84864389287     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.05.014     Document Type: Article

References (44)

1. Alam M.I., Baboota S., Ahuja A., Ali M., Ali J., Sahni J.K. Nanostructured lipid carrier containing CNS acting drug: formulation, optimization and evaluation. Current Nanoscience 2011, 7(6):1014-1027.
2. Alam M.I., Beg S., Samad A., Baboota S., Kohli K., Ali J., et al. Strategy for effective brain drug delivery. European Journal of Pharmaceutical Sciences 2010, 40(5):385-403.
3. Ali J., Ali M., Baboota S., Sahani J.K., Ramassamy C., Dao L., et al. Potential of nanoparticulate drug delivery systems by intranasal administration. Current Pharmaceutical Design 2010, 16(14):1644-1653.
4. Barakat N.S., Omar S.A., Ahmed A.A. Carbamazepine uptake into rat brain following intra-olfactory transport. Journal of Pharmacy and Pharmacology 2006, 58(1):63-72.
5. Bjerre C., Bjork E., Camber O. Bioavailability of the sedative propiomazine after nasal administration in rats. International Journal of Pharmaceutics 1996, 144:217-224.
6. Cryan F.A., Page M.E., Lucki I. Noradrenergic lesions differentially alter the antidepressant-like effect of reboxetine in a modified forced swim test. European Journal of Pharmacology 2002, 436:197-205.
7. Detke M.J., Lu Y., Goldstein D.J., McNamara R.K., Demitrack M.A. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. Journal of Psychiatric Research 2002, 36:383-390.
8. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 1995, 121(1):66-72.
9. Engleman E.A., Perry K.W., Mayle D.A., Wong D.T. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology 1995, 12(4):287-295.
10. Eskandari S., Varshosaz J., Minaiyan M., Tabbakhian M. Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in-vivo pharmacodynamic studies using rat electroshock model. International Journal of Nanomedicine 2011, 6:363-371.
11. Flens M.J., Zaman G.J.R., van der Valk P., Lzquierdo M.A., Schroeijers A.B., Scheffer G.L., et al. Tissue distribution of the multidrug resistance protein. American Journal of Pathology 1996, 148:1237-1247.
12. Garcia-Fuentes M., Prego C., Torres D., Alonso M.J. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. European Journal of Pharmaceutical Sciences 2005, 25(1):133-143.
13. Hermann D.M., Bassetti C.L. Implications of ATP-binding cassette transporters for brain pharmacotherapies. Trends in Pharmacological Sciences 2007, 28:128-134.
14. Jia L., Shen J., Zhang D., Duan C., Liu G., Zheng D., et al. In-vitro and in-vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers. International Journal of Biological Macromolecules 2012, 50(3):523-529.
15. Joshi M., Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. International Journal of Pharmaceutics 2008, 346(1-2):124-132.
16. Kilts C.D. Potential new drug delivery system for antidepressants: an overview. Journal of Clinical Psychiatry 2003, 64:31-33.
17. Kirby L.G., Lucki I. Interaction between the forced swimming test and fluoxetine treatment on extracellular 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in the rat. Journal of Pharmacology and Experimental Therapeutics 1997, 282(2):967-976.
18. Kumar M., Misra A., Babbar A.K., Mishra A.K., Mishra P., Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. International Journal of Pharmaceutics 2008, 358(1-2):285-291.
19. Lantz R.J., Gillespie T.A., Rash T.J., Kuo F., Skinner M., Kuan H.Y., et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metabolism and Disposition 2003, 31(9):1142-1150.
20. Loscher W., Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nature Reviews Neuroscience 2005, 6:591-602.
21. Maggio ET. Intranasal administration of active agents to the central nervous system. US patent 2011;0129462A1; 2011.
22. Manjunath K., Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. Journal of Controlled Release 2005, 107(2):215-228.
23. Martins S., Sarmento B., Ferreira D.C., Souto E.B. Lipid-based colloidal carriers for peptide and protein delivery - liposomes versus lipid nanoparticles. International Journal of Nanomedicine 2007, 2(4):595-607.
24. Mehnert W., Mader K. Solid lipid nanoparticles: production, characterization and applications. Advanced Drug Delivery Reviews 2001, 47:165-196.
25. Misra A., Ganesh S., Shahiwala A., Shah S.P. Drug delivery to the central nervous system: a review. Journal of Pharmacy and Pharmaceutical Sciences 2003, 6(2):252-273.
26. Mistry A., Stolnik S., Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. International Journal of Pharmaceutics 2009, 379(1):146-157.
27. O'Brien F.E., Dinan T.G., Griffin B.T., Cryan J.F. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in-vitro and in-vivo findings. British Journal of Pharmacology 2012, 165:289-312.
28. Pardeike A., Hommoss A., Müller R.H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. International Journal of Pharmaceutics 2009, 366:170-184.
29. Paulus M.P., Dulawa S.C., Ralph R.J., Geyer M.A. Behavioral organization is independent of locomotor activity in 129 and C57 mouse strains. Brain Research 1999, 835:27-36.
30. Paulzen M., Hiemke C., Gründer G. Plasma levels and cerebrospinal fluid penetration by duloxetine in a patient with a non-fatal overdose during a suicide attempt. International Journal of Neuropsychopharmacology 2009, 12(10):1431-1432.
31. Petit-Demouliere B., Chenu F., Bourin M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology 2005, 177(3):245-255.
32. Porsolt R.D., Bertin A., Jalfre M. " Behavioral despair" in rats and mice: strain differences and the effect of imipramine. European Journal of Pharmacology 1978, 51:291-294.
33. Porsolt R.D., Le P.M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
34. Sakane T., Akizuki M., Yamashita S., Nadai T., Hashida M., Sezaki H. The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chemical and Pharmaceutical Bulletin 1991, 39:2456-2458.
35. Scholer N., Hahn H., Muller R.H., Liesenfeld O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. International Journal of Pharmaceutics 2002, 231:167-176.
36. Souto E.B., Muller R.H. SLN and NLC for topical delivery of ketoconazole. Journal of Microencapsulation 2005, 22(5):501-510.
37. Teeranachaideekul V., Souto E.B., Junyaprasert V.B., Muller R.H. Cetyl palmitate-based NLC for topical delivery of Coenzyme Q10 - development, physicochemical characterization and in-vitro release studies. European Journal of Pharmaceutics and Biopharmaceutics 2007, 67:141-148.
38. Thorne R.G., Hanson L.R., Ross T.M., Tung D., Frey W.H. Delivery of interferon-β to the monkey nervous system following intranasal administration. Neuroscience 2008, 152:785-797.
39. Thorne R.G., Pronk G.J., Padmanabhan V., Frey W.H. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004, 127(2):481-496.
40. Tsai M.J., Wu P.C., Huang Y.B., Chang J.S., Lin C.L., Tsai Y.H., et al. Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. International Journal of Pharmaceutics 2012, 423(2):461-470.
41. Urquhart B.L., Kim R.B. Blood-brain barrier transporters and response to CNS-active drugs. European Journal of Clinical Pharmacology 2009, 65:1063-1070.
42. Zhang W.L., Gu X., Bai H., Yang R.H., Dong C.D., Liu J.P. Nanostructured lipid carriers constituted from high-density lipoprotein components for delivery of a lipophilic cardiovascular drug. International Journal of Pharmaceutics 2010, 391:313-321.
43. Zhang X., Pan W., Gan L., Zhu C., Gan Y., Nie S. Preparation of a dispersible pegylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying. Chemical and Pharmaceutical Bulletin 2008, 56(12):1645-1650.
44. Zhao X., Zhao Y., Geng L., Li X., Wang X., Liu Z., et al. Pharmacokinetics and tissue distribution of docetaxel by liquid chromatography-mass spectrometry: evaluation of folate receptor-targeting amphiphilic copolymer modified nanostructured lipid carrier. Journal of Chromatography B 2011, 879(31):3721-3727.